Granules India's US unit gets FDA inspection report with four open observations
The Chantilly, Virginia plant closed its FDA review with a Voluntary Action Indicated classification, but four observations remain open for resolution.
What's new
- Granules Pharmaceuticals received a USFDA Establishment Inspection Report for its Chantilly facility.
- The inspection resulted in a Voluntary Action Indicated classification, avoiding severe enforcement.
- Four Form 483 observations from the March 30 to April 3, 2026, review are being voluntarily addressed.
Why this matters
VAI is the FDA's middle tier. It means the facility avoids immediate sanctions like import alerts or shutdowns, but the company must fix the cited issues to close the loop. For a mid-cap drugmaker, this is a necessary but incomplete step.
What we're watching
- The timeline Granules sets to resolve each Form 483 observation.
- Any follow-up FDA requests or a re-inspection schedule.
- Whether the observations affect pending ANDA filings tied to the Chantilly facility.
The full read
Granules India's US subsidiary, Granules Pharmaceuticals, has received an FDA Establishment Inspection Report for its Chantilly, Virginia facility. The classification is Voluntary Action Indicated, not the more damaging Official Action Indicated. The inspection ran from March 30 to April 3, 2026, and identified four Form 483 observations that the company is addressing. For a drugmaker, a VAI outcome keeps the facility running and avoids immediate enforcement. But it's not a clean bill of health. The observations remain open. The filing provides no detail on their nature or a timeline for closure. What matters now is execution. Granules has the framework to resolve this. The question is how quickly.
Questions answered
- What does a VAI classification mean for the facility?
- It signals the FDA observed conditions requiring corrective action but is not pursuing formal enforcement at this stage. The facility stays operational while Granules addresses the findings.
- Why are the four Form 483 observations significant?
- Form 483 observations are the specific issues an FDA inspector notes during a review. While the company can voluntarily address a VAI classification, unresolved 483s leave a compliance gap until the agency is satisfied.
- Is the Chantilly facility critical to Granules' operations?
- The company describes it as playing a key role in its global manufacturing network, but the filing does not quantify its contribution to revenue or product approvals.
- How does this inspection outcome compare to past FDA actions?
- The filing only details this specific March-April 2026 inspection. A VAI outcome is manageable and avoids the more severe Official Action Indicated classification, but the open observations mean the regulatory process is not fully closed.